Health
GLP-1 medications linked to nutritional deficiencies in adolescent users
ScienceDaily reports that nearly one in six pediatric GLP-1 patients developed nutritional deficiencies within a year.
The short version
- A study of 2,031 patients aged 10 to 17 found that 16.8% developed a diagnosed nutritional deficiency within a year of starting GLP-1 medications.[ScienceDaily]
- Vitamin D deficiency was the most common issue, diagnosed in 12.4% of the children evaluated.[ScienceDaily]
- Researchers found that only 5% of patients received dietary counseling within 30 days of beginning treatment, and under 25% received it within six months.[ScienceDaily]
- Authors suggest providing nutritional support at the start of GLP-1 therapy rather than waiting for deficiencies to emerge.[ScienceDaily]
Key facts
- An analysis of claims data from 2017 to 2022 identified 2,031 GLP-1 users aged 10 to 17 without prior nutritional deficiencies.[ScienceDaily]
- Approximately 16.8% of the pediatric patients were diagnosed with a nutritional deficiency within one year of initiating therapy.[ScienceDaily]
- Vitamin D deficiency affected 12.4% of patients within the first year of treatment.[ScienceDaily]
- Liraglutide accounted for 78.6% of prescriptions in the cohort, dulaglutide for 10.4%, and semaglutide for 9.1%.[ScienceDaily]
- Only 5% of patients received nutritional counseling within 30 days of starting treatment, and fewer than 25% received it within six months.[ScienceDaily]
What remains uncertain
- The long-term effects of adolescent GLP-1 use on skeletal health and pubertal development remain to be fully understood.[ScienceDaily]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.